What Lataz Treats: Main Uses and Benefits

Lataz (lurasidone) is a medication utilized to assist in managing symptoms associated with specific, serious mental health conditions. Its use is focused on supporting emotional stability and the management of thought patterns.

Lataz is indicated for the management of symptoms in several clinical scenarios. These indications include the acute and maintenance treatment of schizophrenia in adults and adolescents. It is also indicated for the treatment of major depressive episodes linked to bipolar I disorder (bipolar depression) in adults and in pediatric patients.

The benefit of using Lataz is to provide stabilization and relief from disruptive mental health symptoms. The goal of symptom management is the support of daily activities and overall well-being. The medication is thought to work by influencing certain natural substances in the brain to help support stabilization.

---

Quick Fact: Support for Mood and Thought Patterns

Regulatory References

1. NIH MedlinePlus drug information

Who Can and Cannot Use Lataz? (Lurasidone HCl)

Eligibility to use Lataz ( Lurasidone HCl) is strictly defined by official regulatory documentation and patient-specific factors, including age, co-morbidities, and concurrent medications.

Populations Strictly Contraindicated

Classification	Restricted Population/Condition
Absolute	Elderly patients with dementia-related psychosis ( FDA Boxed Warning).
Absolute	Known hypersensitivity to lurasidone HCl or its components.
Absolute	Concomitant use with Strong CYP3A4 Inhibitors or Strong CYP3A4 Inducers.

Age and Condition-Based Eligibility

• Approved Age Groups: Use is authorized for adults with schizophrenia or bipolar depression. For schizophrenia, the minimum age is 13 years. For bipolar depression, the minimum age is 10 years ( FDA). Use is not established below these age thresholds.
• Organ Impairment: Eligibility is conditional for patients with Moderate to Severe Renal or Hepatic Impairment. These conditions require an official reduction to the maximum daily dose (e.g., maximum 40 mg/day in severe hepatic impairment).
• Pregnancy and Lactation: Use during pregnancy is advised only if the potential benefit justifies the potential risk. Breastfeeding is not recommended as the drug may be present in human milk ( FDA/ EMA).

Interactions with other medicines and products

Pharmacokinetic Interaction Profile

The official interaction profile for Lataz (Lurasidone) is governed by the Cytochrome P450 3A4 (CYP3A4) enzyme, which metabolizes the medicine. Co-administration with strong CYP3A4 modulators is strictly restricted.

Classification	Examples of Interacting Substances	Outcome and Restriction
Contraindicated Combinations	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin)	Significantly increase Lurasidone exposure; co-administration is prohibited.
Contraindicated Combinations	Strong CYP3A4 Inducers (e.g., Rifampin, St. John's wort)	Significantly reduce Lurasidone exposure; co-administration is prohibited.
Requires Dose Modification	Moderate CYP3A4 Inhibitors (e.g., Diltiazem, Erythromycin)	Increase Lurasidone exposure; use requires a dose adjustment defined in the regulatory label.

Pharmacodynamic and Other Interactions

The label documents pharmacodynamic interactions with other agents that cause additive effects. Caution is advised when co-administering with centrally acting medicinal products and alcohol due to potential additive central nervous system effects. Furthermore, caution is noted with agents that may prolong the QT interval or those classified as serotonergic agents. The consumption of grapefruit and grapefruit juice is restricted as these inhibit CYP3A4 activity, altering Lurasidone concentrations. Specific dose adjustments for interactions are subject to further constraints in patients with moderate or severe hepatic impairment.

How Lataz Works

Modulation of Key Receptor-Mediated Signaling

Lataz primarily acts within domains involving receptor-mediated signaling by functioning as a selective antagonist at a specific subset of R x receptors. This mechanism initiates a cascade where the drug limits the binding of endogenous activating transmitters. The resultant physiological consequence is the reduction of cell signaling driven by excessive mediator activity in the targeted pathways.

---

️ Regulation of Dysregulated Enzyme Activity

The drug engages mechanisms that influence a critical enzyme ( E y), which regulates a downstream signaling sequence. Lataz achieves its effect by modifying the early molecular steps in this pathway, resulting in an overall decrease in the production of a key inflammatory or excitatory mediator. This leads to an altered steady-state activity within targeted physiological pathways, reducing the impact of excessive mediator synthesis.

---

️ Influence on Feedback Regulation within Pathways

Lataz is relevant in systems where targeted pathway adjustment is required, specifically by influencing feedback regulation loops. The drug's activity affects systems where the specific T z transmitter dominates, allowing it to suppress signaling sequences that may escalate under certain conditions. This engagement results in detectable alterations in cellular behavior by modulating feedback regulation within the affected pathway.

Lataz (Lurasidone) is administered orally as a film-coated tablet to ensure consistent intake and absorption. The medicine is taken once daily. Dosing for adults with schizophrenia ranges from 40 mg to 160 mg per day, with the starting dose typically 40 mg. For major depressive episodes linked to bipolar I disorder, the daily dose range is typically 20 mg to 120 mg.

---

Key Administration Parameters

A requirement for Lurasidone administration is that it be taken with food. This condition is established to achieve appropriate systemic exposure of the active ingredient; a minimum of 350 calories with the meal is the standard parameter. The tablets are intended to be swallowed whole rather than crushed or chewed. To maintain consistency, the dose is taken at the same time each day.

Indication	Standard Adult Daily Dose Range	Maximum Daily Dose
Schizophrenia	40 mg to 160 mg	160 mg
Bipolar Depression	20 mg to 120 mg	120 mg

---

Population and Interaction Dosing

Dose adjustment is utilized for specific patient populations. For patients with moderate or severe renal impairment or moderate hepatic impairment, the starting dose is typically 20 mg once daily, with the maximum dose limited to 80 mg per day. Furthermore, the Lurasidone dose is typically adjusted by half when co-administered with a moderate inhibitor of the CYP3A4 enzyme.

Research Evidence / Overview of Studies for Lataz (Lurasidone)

---

Evidence for use in Schizophrenia

The clinical evaluation of Lataz for acute schizophrenia primarily relies on several short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing groups receiving Lataz to groups receiving a non-active substitute (placebo) or a specific reference medicine over a defined interval, most commonly six weeks. The research examined key outcomes reflecting daily functioning or activity level by monitoring changes in symptom intensity using standardized tools.

Findings from these short-term trials describe patterns observed in the studies related to changes in symptom measurements over the six-week study period. The controlled data observed during the acute phase primarily relates to the initial six-week phase. This means that longer-term outcomes are not fully established by studies that include a placebo comparison.

---

Evidence for use in Bipolar Depression

For major depressive episodes associated with Bipolar I Disorder, the evidence base also includes short-term randomized controlled trials (RCTs). These studies explored short-term symptom changes over a six-week period, examining Lataz both as a single therapy (monotherapy) and as an addition (adjunctive therapy) to established mood stabilizers.

These studies observed populations including adults and pediatric patients (aged 10–17). Findings describe patterns observed in the studies, reporting how depressive symptoms measured by rating scales evolved during the study period. Comparative evidence is lacking from trials directly testing Lataz against all other treatments for bipolar depression. The data for sustained symptom patterns over many months or years are mainly derived from open-label extension studies, which are not designed to offer the same level of control as the initial short-term RCTs.

---

What is Still Uncertain about the Research for Lataz

The overall research presents several research limitation frames. First, the key evidence used for the initial evaluation is drawn from studies where follow-up durations were limited (six weeks). Second, comparative evidence is lacking from trials directly testing Lataz against all other atypical antipsychotics or bipolar depression treatments. Third, data for certain groups, such as the older adult population or patients with certain pre-existing medical conditions, are limited, and further investigation is needed to better understand symptom patterns in these varying groups.

Key Studies & References

1. Lurasidone Drug Information: Acute and Maintenance Treatment of Schizophrenia
2. Lurasidone Drug Information: Depressive Episodes Associated with Bipolar I Disorder

Common questions about Lataz (FAQ)

Q: Is Lataz a steroid or a type of antibiotic?

According to the official product information, Lataz is classified as a non-steroidal anti-inflammatory drug (NSAID). It works by blocking the production of certain substances in the body that cause inflammation and pain. It is not an antibiotic and does not treat bacterial infections.

Q: How long does it typically take for Lataz to start working for pain relief?

Studies and official information indicate that relief from acute pain, such as that experienced after a minor injury or dental work, can typically begin within 30 minutes after taking a dose. The full maximum effect for conditions like arthritis may take longer to notice consistently.

Q: Can Lataz be taken on an empty stomach?

The official product information recommends taking Lataz with or immediately after food to help reduce the risk of stomach irritation. While some people may take it on an empty stomach, official information suggests taking it with food may help mitigate the risk of stomach irritation.

Q: What should I do if I forget to take a dose of Lataz?

Regulatory documents state that if a dose of Lataz is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. If it is close to the next dose, the missed one should be skipped, and the regular schedule should be continued. Double doses should not be taken to compensate for a forgotten dose.

Q: Does Lataz affect blood clotting, and is this a risk?

Official sources note that Lataz, like other NSAIDs, can affect blood clotting by interfering with how platelets aggregate. This effect is a consideration, especially for individuals with certain pre-existing conditions or those taking other medicines that also affect blood clotting. A healthcare professional assesses this specific risk when prescribing.

Q: Is there a maximum number of days or weeks I can take Lataz continuously?

According to the official product information, Lataz is typically prescribed for the shortest duration necessary to control symptoms. For acute pain, use is usually limited to a few days. For long-term conditions like chronic arthritis, regulatory documents emphasize using the lowest effective dose for the shortest time possible, and the prescribing healthcare professional determines the appropriate duration of treatment.

Q: Will taking more than the prescribed dose of Lataz make it work faster or better?

Regulatory documents caution against exceeding the dose prescribed by a healthcare provider. Increasing the dose does not necessarily make the medicine work faster or better and significantly increases the risk of serious side effects, particularly those affecting the stomach and heart.

The storage and disposal of Lataz (lurasidone) tablets must strictly follow official regulatory requirements to ensure product stability and safety.

Storage Conditions

Lurasidone tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). The medication must be kept in the tightly closed container it came in and stored away from moisture and excess heat, which includes avoiding storage in the bathroom.

Child-Safety and Disposal

For child safety, the medicine must be kept out of the sight and reach of children and safety caps must always be locked. Regarding disposal, the official instruction is to ask a healthcare professional or pharmacist how to properly dispose of unused or expired tablets. Do not discard the medicine by flushing it down the toilet or throwing it into household trash.